MD Conference Express ISC 2012 - (Page 10)
n
C L I N I C A L
T R I A L
H I G H L I G H T S
Apixaban Superior to Warfarin in Patients with Atrial Fibrillation as well as Prior Stroke or TIA
Written by Rita Buckley
The recent Apixaban Compared with Warfarin in Patients with Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack trial [Granger CB et al. N Engl J Med 2011; ARISTOTLE; NCT00412984] found apixaban to be superior to warfarin for stroke prevention in a wide range of atrial fibrillation (AF) patients, with significantly lower bleeding risk and lower risk of all-cause mortality [Littrell R, Flaker G. Expert Rev Cardiovasc Ther 2012]. J. Donald Easton, MD, FAHA, University of California, San Francisco, California, USA, presented results of a comparison of apixaban with warfarin in patients with AF and prior stroke or transient ischemic attack (TIA). ARISTOTLE was a randomized, double-blind, doubledummy trial that included subjects who were aged ≥75 years and had AF and at least one additional risk factor for stroke (previous stroke, TIA, or systemic embolism [SE]; symptomatic heart failure within the previous 3 months or left ventricular ejection fraction ≤40%; diabetes mellitus; or hypertension requiring pharmacologic treatment). A total of 18,201 patients were randomized to apixaban 5 mg oral BID or warfarin (target INR 2 to 3). The primary outcome was ischemic or hemorrhagic stroke or SE. The trial was designed to test for noninferiority, with key secondary objectives of testing for superiority with respect to the primary outcome and to the rates of major bleeding and death from any cause. The primary objective of the stroke substudy was to determine whether apixaban, as compared with warfarin, had the same advantages in patients with prior stroke or TIA (n=3436) as in all patients (n=14,765) with AF Table 1. Stroke Substudy Efficacy Outcomes.
Prior Stroke or TIA Apixaban n (Rate*) Primary Efficacy Outcome (Stroke or Systemic Embolism) Stroke Hemorrhagic Ischemic or uncertain Disabling or fatal Myocardial infarction Cardiovascular death Death from any cause
.
in the ARISTOTLE trial. The primary efficacy outcome was ischemic or hemorrhagic stroke or SE. The primary safety outcome was major bleeding according to the International Society of Thrombosis and Hemostasis (ISTH) definition. The demographic and clinical characteristics of the Prior Stroke/TIA patients compared with the No Prior Stroke/TIA patients were essentially the same, with 19.5% of the 18,201 ARISTOTLE patients having had a prior stroke or TIA. The only important difference was in the CHADS2 score (mean, SD): 3.7 (0.9) for the Prior Stroke/TIA group versus 1.7 (0.8) for the No Prior Stroke/TIA group. Only 15% of the No Prior Stroke/TIA group had a CHADS2 score that high. The primary outcome data (Figure 1) showed a considerably higher event rate in the warfarin/Prior Stroke group compared with the apixaban/Prior Stroke group, indicating a greater absolute benefit in the apixaban group. In the hazard ratio outcomes, all p values were nonsignificant, demonstrating comparable benefit in the Prior Stroke/TIA and No Prior Stroke/TIA groups. Efficacy outcomes also had nonsignificant interaction p values, indicating a consistent benefit between the two groups (Table 1). The safety outcomes showed that the benefit always accrued to apixaban. Nonsignificant interaction p values indicated that the results in both groups were equally beneficial. Summary data showed that treatment with apixaban compared with warfarin in patients with AF and prior stroke or TIA reduced stroke and SE by 24%, major bleeding by 27%, intracranial bleeding by 63%, and mortality by 11%.
No Prior Stroke or TIA Apixaban n (Rate*) 139 (1.01) 132 (0.96) 28 (0.20) 105 (0.76) 46 (0.33) 73 (0.53) 236 (1.68) 474 (3.37) Warfarin n (Rate*) 167 (1.23) 154 (1.14) 47 (0.34) 107 (0.79) 76 (0.56) 74 (0.54) 268 (1.94) 519 (3.75) HR (95% CI) Apixaban vs Warfarin 0.82 (0.65-1.03) 0.84 (0.67-1.03) 0.59 (0.37-0.94) 0.97 (0.74-1.26) 0.60 (0.41-0.86) 0.97 (0.70-1.34) 0.87 (0.73-1.03) 0.90 (0.79-1.02)
Warfarin n (Rate*) 98 (3.24) 96 (3.17) 31 (1.00) 68 (2.23) 46 (1.49) 28 (0.91) 76 (2.41) 150 (4.77)
HR (95% CI) Apixaban vs Warfarin 0.76 (0.56-1.03) 0.71 (0.52-0.98) 0.40 (0.21-0.78) 0.86 (0.60-1.22) 0.87 (0.57-1.34) 0.62 (0.34-1.14) 0.98 (0.71-1.35) 0.89 (0.70-1.12)
p value (interaction)
73 (2.46) 67 (2.26) 12 (0.40) 57 (1.92) 39 (1.31) 17 (0.57) 72 (2.35) 129 (4.22)
0.71 0.40 0.35 0.61 0.18 0.20 0.53 0.89
*Rate per 100 patient/years of follow-up; Reproduced with permission from JD Easton, MD.
10
April 2012
www.mdconferencexpress.com
http://www.mdconferencexpress.com
http://www.mdconferencexpress.com
Table of Contents for the Digital Edition of MD Conference Express ISC 2012
MD Conference Express ISC 2012
From Neurovascular Laboratory to Clinic: A Journey Through Time
No Compelling Evidence to Use Warfarin or Aspirin in Heart Failure Patients
AXIS 2 Clinical Outcomes No Different Than Placebo
SAMMPRIS: 30-Day Outcomes After Angioplasty and Stenting
Aggressive Medical Therapy Benefits Those Who Fail Antithrombotic Therapy
Initial Clinical Results with TREVO® Mechanical Thrombectomy Device are Promising
Linking sICH Definitions to Outcomes
Solitaire™ Flow Restoration Device Achieves Successful Recanalization Free of Symptomatic Hemorrhage Transformation
FIA II Seeks Genetic Underpinnings of Familial Intracranial Aneurysm
SPS3 Study Does Not Support the Use of Combination Therapy for Stroke Prevention
Novel Agent NA-1 Proves that Ischemic Neuroprotection is Possible in Older Patients
Acute Endovascular Treatment
Neuroimaging
Stroke Guidelines: Current Recommendations in Principle and Practice
The Rising Trend of Ischemic Stroke in the Young
Advanced Neuroimaging Adds Time, Reduces Endovascular Treatment in Clinical Practice
MD Conference Express ISC 2012
https://www.nxtbook.com/nxtbooks/md_conference_express/isc2012
https://www.nxtbookmedia.com